SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-097100
Filing Date
2023-12-20
Accepted
2023-12-20 06:06:15
Documents
13
Period of Report
2023-12-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea190382-8k_jasper.htm   iXBRL 8-K 43359
  Complete submission text file 0001213900-23-097100.txt   264248

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE jspr-20231215.xsd EX-101.SCH 3928
3 XBRL DEFINITION FILE jspr-20231215_def.xml EX-101.DEF 26833
4 XBRL LABEL FILE jspr-20231215_lab.xml EX-101.LAB 37093
5 XBRL PRESENTATION FILE jspr-20231215_pre.xml EX-101.PRE 25457
7 EXTRACTED XBRL INSTANCE DOCUMENT ea190382-8k_jasper_htm.xml XML 5621
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 231499331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)